Trimipramine 25mg tablets

국가: 영국

언어: 영어

출처: MHRA (Medicines & Healthcare Products Regulatory Agency)

유효 성분:

Trimipramine maleate

제공처:

Phoenix Healthcare Distribution Ltd

ATC 코드:

N06AA06

INN (International Name):

Trimipramine maleate

복용량:

25mg

약제 형태:

Oral tablet

관리 경로:

Oral

수업:

No Controlled Drug Status

처방전 유형:

Valid as a prescribable product

제품 요약:

BNF: 04030100

환자 정보 전단

PACKAGE LEAFLET:
INFORMATION FOR THE USER
TRIMIPRAMINE 25MG TABLETS
(trimipramine maleate)
READ ALL OF THIS LEAFLET CAREFULLY
BEFORE YOU START TAKING THIS MEDICINE
• Keep this leaflet. You may need to
read it again.
• If you have any further questions, ask
your doctor or pharmacist.
• This medicine has been prescribed
for you. Do not pass it on to others. It
may harm them, even if their
symptoms are the same as yours.
• If any of the side effects gets serious,
or if you notice any side effects not
listed in this leaflet, please tell your
doctor or pharmacist.
IN THIS LEAFLET:
1. What Trimipramine 25mg Tablets
are and what they are used for
2. Before you take Trimipramine
25mg Tablets
3. How to take Trimipramine 25mg
Tablets
4. Possible side effects
5. How to store Trimipramine 25mg
Tablets
6. Further information
1. WHAT TRIMIPRAMINE 25MG TABLETS
ARE AND WHAT THEY ARE USED FOR
Your tablets contain a medicine called
trimipramine. This belongs to a group of
medicines called antidepressants.
Trimipramine 25mg Tablets can be used
to treat depression. They are especially
useful for treating depression in people
who also have problems sleeping, stress
(anxiety) or feel irritable and restless
(agitation).
2. BEFORE YOU TAKE TRIMIPRAMINE
25MG TABLETS
DO NOT TAKE THIS MEDICINE AND TELL
YOUR DOCTOR IF:
Ï
You are allergic (hypersensitive) to
trimipramine or any of the other
ingredients of Trimipramine 25mg
Tablets (listed in Section 6 Further
information).
Signs of an allergic reaction include: a
rash, swelling or breathing problems,
swelling of your lips, face, throat or
tongue
Ï
You have had a heart attack
Ï
You have had any other heart
problems including slow or uneven
heart beat
Ï
You have severe liver problems
Ï
You have mania (signs include very
high mood, energy and unusual
behaviour)
Ï
You are breast-feeding
Do not take this medicine if this applies to
you. If you are not sure, talk to your
doctor or pharmacist before taking
Trimipramine 25mg Tablets.
TAKE SPECIAL CARE WITH
TRIMIPRAMINE 25MG TABLETS
THO

제품 특성 요약

SUMMARY OF PRODUCT CHARACTERISTICS
1
NAME OF THE MEDICINAL PRODUCT
Trimipramine 25mg Tablets
2
QUALITATIVE AND QUANTITATIVE COMPOSITION
Trimpramine 25mg tablets contain Trimipramine Maleate 34.87mg
equivalent to
25mg trimipramine per tablet.
Excipient(s) with known effect: Lactose Monohydrate
For full list of excipients, see section 6.1
3
PHARMACEUTICAL FORM
Tablet
4
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Trimipramine has a potent antidepressant action similar to that of
other tricyclic
antidepressants.
It
also
possesses
pronounced
sedative
action.
It
is,
therefore,
indicated in the treatment of depressive illness, especially where
sleep disturbance,
anxiety or agitation are presenting symptoms. Sleep disturbance is
controlled within
24 hours and true antidepressant action follows within 7 to 10 days.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
_Adults:_ For depression 50-75 mg/day initially increasing to 150-300
mg/day in
divided doses or one dose at night. The maintenance dose is 75-150
mg/day.
_Elderly:_ 10-25 mg three times a day initially. The initial dose
should be
increased with caution under close supervision. Half the normal
maintenance
dose may be sufficient to produce a satisfactory clinical response.
Paediatric population: Not recommended.
Method of administration
Oral
4.3
CONTRAINDICATIONS
Hypersensitivity to trimipramine maleate or to any of the excipients
listed in
Section 6.1
Recent myocardial infarction.
Any degree of heart block or other cardiac arrhythmias.
Mania.
Severe liver disease.
During breast feeding.
4.4
Special warnings and precautions for use
_Suicide/suicidal thoughts or clinical worsening _
_ _
Depression is associated with an increased risk of suicidal thoughts,
self-harm
and
suicide
(suicide-related
events).
This
risk
persists
until
significant
remission occurs. As improvement may not occur during the first few
weeks
or
more
of
treatment,
patients
should
be
closely
monitored
until
such
improvement occurs. It is general clinical experience that the risk of
suicide